130 related articles for article (PubMed ID: 9569955)
1. End-stage renal interstitial fibrosis in an adult ten years after ifosfamide therapy.
Friedlaender MM; Haviv YS; Rosenmann E; Peylan-Ramu N
Am J Nephrol; 1998; 18(2):131-3. PubMed ID: 9569955
[TBL] [Abstract][Full Text] [Related]
2. Severe, irreversible renal failure after ifosfamide treatment. A clinicopathologic report of two patients.
Berns JS; Haghighat A; Staddon A; Cohen RM; Schmidt R; Fisher S; Rudnick MR; Tomaszewski JE
Cancer; 1995 Aug; 76(3):497-500. PubMed ID: 8625132
[TBL] [Abstract][Full Text] [Related]
3. Chronic Ifosfamide toxicity: kidney pathology and pathophysiology.
Akilesh S; Juaire N; Duffield JS; Smith KD
Am J Kidney Dis; 2014 May; 63(5):843-50. PubMed ID: 24518127
[TBL] [Abstract][Full Text] [Related]
4. Late reversibility of chronic ifosfamide-associated nephrotoxicity in a child.
Ashraf MS; Skinner R; English MW; Craft AW; Pearson AD
Med Pediatr Oncol; 1997 Jan; 28(1):62-4. PubMed ID: 8950339
[TBL] [Abstract][Full Text] [Related]
5. Tubulointerstitial nephritis following high-dose ifosfamide in three breast cancer patients.
Hill PA; Prince HM; Power DA
Pathology; 2000 Aug; 32(3):166-70. PubMed ID: 10968388
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide and paediatrics: should this marriage be saved?
Womer RB
Eur J Cancer; 1996 Jun; 32A(7):1100-1. PubMed ID: 8758237
[No Abstract] [Full Text] [Related]
7. Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
Oberlin O; Fawaz O; Rey A; Niaudet P; Ridola V; Orbach D; Bergeron C; Defachelles AS; Gentet JC; Schmitt C; Rubie H; Munzer M; Plantaz D; Deville A; Minard V; Corradini N; Leverger G; de Vathaire F
J Clin Oncol; 2009 Nov; 27(32):5350-5. PubMed ID: 19826134
[TBL] [Abstract][Full Text] [Related]
8. Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas.
Marina NM; Poquette CA; Cain AM; Jones D; Pratt CB; Meyer WH
J Pediatr Hematol Oncol; 2000; 22(2):112-8. PubMed ID: 10779023
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide nephrotoxicity in children: histopathological features in two cases.
Morland BJ; Mann JR; Milford DV; Raafat F; Stevens MC
Med Pediatr Oncol; 1996 Jul; 27(1):57-61. PubMed ID: 8614393
[TBL] [Abstract][Full Text] [Related]
10. Progressive glomerular toxicity of ifosfamide in children.
Prasad VK; Lewis IJ; Aparicio SR; Heney D; Hale JP; Bailey CC; Kinsey SE
Med Pediatr Oncol; 1996 Sep; 27(3):149-55. PubMed ID: 8699991
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
Skinner R; Cotterill SJ; Stevens MC
Br J Cancer; 2000 May; 82(10):1636-45. PubMed ID: 10817497
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of ifosfamide neurotoxicity with dexmedetomidine.
Bernard PA; McCabe T; Bayliff S; Hayes D
J Oncol Pharm Pract; 2010 Dec; 16(4):262-5. PubMed ID: 20118215
[TBL] [Abstract][Full Text] [Related]
13. Renal dysfunctions secondary to ifosfamide treatment in children.
Tokuc G; Yalçiner A; Kebudi R; Dogan S; Görgün O; Ayan I
J Exp Clin Cancer Res; 1997 Jun; 16(2):227-30. PubMed ID: 9261752
[TBL] [Abstract][Full Text] [Related]
14. [Ifosphamide nephrotoxicity].
Ensergueix G; Karras A
Nephrol Ther; 2018 Apr; 14 Suppl 1():S125-S131. PubMed ID: 29606257
[TBL] [Abstract][Full Text] [Related]
15. Karyomegalic-like nephropathy, Ewing's sarcoma and ifosfamide therapy.
McCulloch T; Prayle A; Lunn A; Watson AR
Pediatr Nephrol; 2011 Jul; 26(7):1163-6. PubMed ID: 21424282
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide in pediatric solid tumors.
Carli M; Passone E; Perilongo G; Bisogno G
Oncology; 2003; 65 Suppl 2():99-104. PubMed ID: 14586158
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M
Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations.
Canpolat C; Pearson P; Robertson R; Jaffe N
Med Pediatr Oncol; 1996 Jan; 26(1):36-47. PubMed ID: 7494510
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide induced renal rickets.
Lionel AP; Chinnaswamy G; John RR; Mathai S
Indian J Pediatr; 2014 Sep; 81(9):943-5. PubMed ID: 23912821
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report.
Cherry MA; Bhardwaj H; Hopps S; Srour S; Pant S
J Oncol Pharm Pract; 2013 Sep; 19(3):261-4. PubMed ID: 23135805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
